{"id":4060,"date":"2018-05-16T21:47:33","date_gmt":"2018-05-16T21:47:33","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=4060"},"modified":"2020-12-13T18:14:09","modified_gmt":"2020-12-13T23:14:09","slug":"eiger-press-release-2","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/ur\/2018\/05\/16\/eiger-press-release-2\/","title":{"rendered":"JAMA \u0627\u0633\u0679\u0688\u06cc \u06a9\u06cc \u0627\u06cc\u0691\u06cc\u0648\u06ba \u067e\u0631\u060c \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u0627\u06cc\u0641 \u0688\u06cc \u0627\u06d2 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u062d\u0635\u0648\u0644 \u06a9\u06d2 \u0644\u06cc\u06d2 PRF \u0627\u0648\u0631 Eiger Biopharmaceuticals \u06a9\u06d2 \u0633\u0627\u062a\u06be\u06cc"},"content":{"rendered":"<p>[et_pb_section fb_built=\u201d1\u2033 _builder_version=\u201d3.22\u2033][et_pb_row _builder_version=\u201d3.25\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d][et_pb\u201d=4_column _builder_version=\u201d3.25\u2033 custom_padding=\u201d|||\u201d custom_padding__hover=\u201d|||\u201d][et_pb_text _builder_version=\u201d4.6.5\u2033 background_size=\u201dinitial\u201d background_position=\u201dtop_left\u201d background_repeat=\u201drepeat\u201d hover_enabled=\u201d0\u2033 sticky_enabled=\u201d0\u2033]<\/p>\n<p>\u062a\u0639\u0627\u0648\u0646 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d2 \u0639\u0644\u0627\u062c \u06a9\u06d2 \u0644\u0626\u06d2 \u067e\u06c1\u0644\u06cc \u062c\u0645\u0639 \u06a9\u0631\u0627\u0646\u06d2 \u06a9\u06cc \u0646\u0634\u0627\u0646\u062f\u06c1\u06cc \u06a9\u0631\u062a\u0627 \u06c1\u06d2\u06d4 \u0627\u06af\u0631 \u0645\u0646\u0638\u0648\u0631\u06cc \u062f\u06cc \u062c\u0627\u062a\u06cc \u06c1\u06d2\u060c \u062a\u0648 \u0628\u0686\u06d2 \u06a9\u0644\u06cc\u0646\u06cc\u06a9\u0644 \u0679\u0631\u0627\u0626\u0644 \u06a9\u06d2 \u0628\u062c\u0627\u0626\u06d2 \u0646\u0633\u062e\u06d2 \u06a9\u06d2 \u0630\u0631\u06cc\u0639\u06d2 \u062f\u0648\u0627 \u062a\u06a9 \u0631\u0633\u0627\u0626\u06cc \u062d\u0627\u0635\u0644 \u06a9\u0631 \u0633\u06a9\u062a\u06d2 \u06c1\u06cc\u06ba!!<\/p>\n<p>\u06c1\u0645\u0627\u0631\u06cc \u062a\u0627\u0632\u06c1 \u062a\u0631\u06cc\u0646 \u067e\u0631\u06cc\u0633 \u0631\u06cc\u0644\u06cc\u0632 \u06cc\u06c1\u0627\u06ba \u067e\u0691\u06be\u06cc\u06ba:<\/p>\n<ul>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">\u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646 \u0646\u06d2 \u0627\u06cc\u06af\u0631 \u0628\u0627\u0626\u06cc\u0648 \u0641\u0627\u0631\u0645\u0627\u0633\u06cc\u0648\u0679\u06cc\u06a9\u0644 \u06a9\u06d2 \u0633\u0627\u062a\u06be \u062a\u0639\u0627\u0648\u0646 \u0627\u0648\u0631 \u0641\u0631\u0627\u06c1\u0645\u06cc \u06a9\u06d2 \u0645\u0639\u0627\u06c1\u062f\u06d2 \u06a9\u0627 \u0627\u0639\u0644\u0627\u0646 \u06a9\u06cc\u0627\u00a0<\/a><\/li>\n<li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">JAMA \u0645\u06cc\u06ba \u0634\u0627\u0626\u0639 \u06c1\u0648\u0646\u06d2 \u0648\u0627\u0644\u0627 \u0639\u0627\u0644\u0645\u06cc \u0645\u0637\u0627\u0644\u0639\u06c1 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06d2 \u0633\u0627\u062a\u06be \u0639\u0644\u0627\u062c \u062a\u0644\u0627\u0634 \u06a9\u0631\u062a\u0627 \u06c1\u06d2 \u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u06a9\u06d2 \u0633\u0627\u062a\u06be \u0628\u0686\u0648\u06ba \u0645\u06cc\u06ba \u0628\u0642\u0627 \u0628\u0691\u06be\u0627\u062a\u0627 \u06c1\u06d2<\/a><\/li>\n<\/ul>\n<div id=\"attachment_9151\" style=\"width: 285px\" class=\"wp-caption aligncenter\"><img loading=\"lazy\" decoding=\"async\" aria-describedby=\"caption-attachment-9151\" class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/><p id=\"caption-attachment-9151\" class=\"wp-caption-text\">\u0632\u0648\u0626\u06cc \u0627\u0648\u0631 \u06a9\u0627\u0631\u0644\u06cc \u0628\u0648\u0633\u0679\u0646 \u06a9\u06d2 \u0627\u067e\u0646\u06d2 \u062a\u0627\u0632\u06c1 \u062a\u0631\u06cc\u0646 \u06a9\u0644\u06cc\u0646\u06cc\u06a9\u0644 \u0679\u0631\u0627\u0626\u0644 \u06a9\u06d2 \u062f\u0648\u0631\u06d2 \u06a9\u06d2 \u062f\u0648\u0631\u0627\u0646 \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u0627 \u0639\u0644\u0627\u062c \u06a9\u0631\u0648\u0627 \u0631\u06c1\u06d2 \u06c1\u06cc\u06ba\u06d4<\/p><\/div>\n<p>&nbsp;<\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"<p>JAMA \u0627\u0633\u0679\u0688\u06cc \u06a9\u06cc \u0627\u06cc\u0691\u06cc\u0648\u06ba \u067e\u0631\u060c \u0644\u0648\u0646\u0627\u0641\u0627\u0631\u0646\u06cc\u0628 \u06a9\u06cc \u0627\u06cc\u0641 \u0688\u06cc \u0627\u06d2 \u06a9\u06cc \u0645\u0646\u0638\u0648\u0631\u06cc \u06a9\u06d2 \u062d\u0635\u0648\u0644 \u06a9\u06d2 \u0644\u06cc\u06d2 PRF \u0627\u0648\u0631 Eiger Biopharmaceuticals \u067e\u0627\u0631\u0679\u0646\u0631\u06d4 \t<\/p>","protected":false},"author":2,"featured_media":11817,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"image","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"<p>Collaboration marks the first submission for the treatment of Progeria. If approved, children may access drug by prescription instead of clinical trial!!<\/p><p>Read our latest press releases here:<\/p><ul><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/PRF-Eiger-FINAL-Press-release.pdf\">Progeria Research Foundation Announces Collaboration and Supply Agreement with Eiger BioPharmaceuticals\u00a0<\/a><\/li><li><a href=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/04\/PRF-JAMA-Announcement_Press-Release-1.pdf\">Global Study Published in JAMA Finds Treatment with Lonafarnib Extends Survival in Children with Progeria<\/a><\/li><\/ul>[caption id=\"attachment_9151\" align=\"aligncenter\" width=\"275\"]<img class=\"size-medium wp-image-9151\" src=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/12\/getting-drug-zoeycarly-April-2016-1-275x300.jpg\" alt=\"\" width=\"275\" height=\"300\" \/> Zoey and Carly getting their lonafarnib treatment during their latest clinical trial visit to Boston.[\/caption]<p>\u00a0<\/p>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-4060","post","type-post","status-publish","format-image","has-post-thumbnail","hentry","category-news","post_format-post-format-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/ur\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/ur\/2018\/05\/16\/eiger-press-release-2\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-05-16T21:47:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-13T23:14:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"300\" \/>\n\t<meta property=\"og:image:height\" content=\"225\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Karen Betournay\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Karen Betournay\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 \u0645\u0646\u0679\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"},\"author\":{\"name\":\"Karen Betournay\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\"},\"headline\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"},\"wordCount\":159,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"ur\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\",\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"datePublished\":\"2018-05-16T21:47:33+00:00\",\"dateModified\":\"2020-12-13T23:14:09+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb\"},\"inLanguage\":\"ur\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"ur\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg\",\"width\":300,\"height\":225},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ur\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ur\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946\",\"name\":\"Karen Betournay\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ur\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g\",\"caption\":\"Karen Betournay\"},\"url\":\"https:\/\/www.progeriaresearch.org\/ur\/author\/karenb\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/ur\/2018\/05\/16\/eiger-press-release-2\/","og_locale":"en_US","og_type":"article","og_title":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","og_description":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib.","og_url":"https:\/\/www.progeriaresearch.org\/ur\/2018\/05\/16\/eiger-press-release-2\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2018-05-16T21:47:33+00:00","article_modified_time":"2020-12-13T23:14:09+00:00","og_image":[{"width":300,"height":225,"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","type":"image\/jpeg"}],"author":"Karen Betournay","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"Karen Betournay","Est. reading time":"1 \u0645\u0646\u0679"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"author":{"name":"Karen Betournay","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946"},"headline":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"},"wordCount":159,"commentCount":0,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","articleSection":["News"],"inLanguage":"ur","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","url":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/","name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","datePublished":"2018-05-16T21:47:33+00:00","dateModified":"2020-12-13T23:14:09+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb"},"inLanguage":"ur","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/"]}]},{"@type":"ImageObject","inLanguage":"ur","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2018\/05\/getting-drug-zoeycarly-April-2016-300x225-1.jpg","width":300,"height":225},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/nl\/2018\/05\/16\/eiger-press-release-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"On the Heels of the JAMA Study, PRF and Eiger BioPharmaceuticals Partner to Pursue FDA Approval of Lonafarnib"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646","description":"\u0628\u0686\u0648\u06ba \u06a9\u06d2 \u0644\u06cc\u06d2 \u2665 \u0639\u0644\u0627\u062c \u06a9\u06d2 \u0644\u06cc\u06d2","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ur"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u067e\u0631\u0648\u062c\u06cc\u0631\u06cc\u0627 \u0631\u06cc\u0633\u0631\u0686 \u0641\u0627\u0624\u0646\u0688\u06cc\u0634\u0646","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"ur","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/2be6cec85c11aaef7a7602636c5b9946","name":"\u06a9\u06cc\u0631\u0646 \u0628\u06cc\u0679\u0648\u0631\u0646\u06d2","image":{"@type":"ImageObject","inLanguage":"ur","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/78c0520933a7d708c5e1a5788ec6799d5e2ad6a2a6d4ff2ca1e512861d12f533?s=96&d=mm&r=g","caption":"Karen Betournay"},"url":"https:\/\/www.progeriaresearch.org\/ur\/author\/karenb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/posts\/4060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/comments?post=4060"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/posts\/4060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/media\/11817"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/media?parent=4060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/categories?post=4060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/ur\/wp-json\/wp\/v2\/tags?post=4060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}